Vanguard Group Inc. Purchases 251,939 Shares of Guardant Health, Inc. $GH

Vanguard Group Inc. boosted its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 2.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 12,160,768 shares of the company’s stock after purchasing an additional 251,939 shares during the quarter. Vanguard Group Inc. owned about 0.10% of Guardant Health worth $1,242,101,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. B. Metzler seel. Sohn & Co. AG purchased a new position in Guardant Health in the fourth quarter worth about $911,000. M&T Bank Corp purchased a new stake in shares of Guardant Health during the fourth quarter valued at approximately $6,833,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Guardant Health by 8.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,760 shares of the company’s stock valued at $3,857,000 after acquiring an additional 3,071 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Guardant Health by 37.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,603 shares of the company’s stock valued at $674,000 after acquiring an additional 1,782 shares in the last quarter. Finally, CWM LLC raised its holdings in Guardant Health by 14.3% in the 4th quarter. CWM LLC now owns 2,309 shares of the company’s stock worth $236,000 after acquiring an additional 289 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Evercore set a $110.00 price objective on Guardant Health in a research report on Friday, February 20th. Mizuho set a $135.00 target price on Guardant Health in a report on Friday, January 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. Citigroup upped their price target on Guardant Health from $135.00 to $150.00 and gave the company a “buy” rating in a report on Friday, February 20th. Finally, Barclays dropped their price objective on Guardant Health from $130.00 to $115.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Nineteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $128.63.

Insider Buying and Selling

In related news, insider Terilyn J. Monroe sold 3,832 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $92.68, for a total transaction of $355,149.76. Following the completion of the transaction, the insider directly owned 20,990 shares in the company, valued at approximately $1,945,353.20. The trade was a 15.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Brian Bell sold 3,000 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $87.04, for a total transaction of $261,120.00. Following the completion of the sale, the chief financial officer directly owned 43,601 shares of the company’s stock, valued at $3,795,031.04. This represents a 6.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 8,596 shares of company stock valued at $775,767 in the last 90 days. Corporate insiders own 6.10% of the company’s stock.

Guardant Health Stock Performance

Shares of Guardant Health stock opened at $87.60 on Friday. The stock has a market cap of $11.61 billion, a P/E ratio of -26.47 and a beta of 1.49. The stock’s fifty day moving average is $89.30 and its 200 day moving average is $95.91. Guardant Health, Inc. has a one year low of $36.36 and a one year high of $120.74.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. The business’s revenue for the quarter was up 39.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.62) earnings per share. Analysts predict that Guardant Health, Inc. will post -2.87 EPS for the current year.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.